Fate Therapeutics

a clinical-stage biopharmaceutical company in San Diego, United States

FATE Nasdaq ISIN US31189P1021 SEC CIK 1434316 LEI 549300L14Q4UHOODLA90
Follow Fate Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$30.7M +4.8% vs same quarter last year
EPS, diluted −$0.25 +7.4% vs same quarter last year
Operating cash flow −$27.8M −14.1% vs same quarter last year
Revenue by quarter
$1.9M
$1.6M
$1.9M
$1.7M
$1.4M
$1.3M
$2.1M
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$6.6M−$136.3M
FY24$13.6M−$186.3M
FY23$63.5M−$160.9M
FY22$96.3M−$281.7M
FY21$55.8M−$212.2M
FY20$31.4M−$173.4M
FY19$10.7M−$98.1M
FY18$4.7M−$66.6M
FY17$4.1M−$43M
FY16$4.4M−$33.5M
FY15$2.4M−$30M
FY14-−$25.9M
FY13$971K−$20.9M
FY12$2.7M−$14.2M
FY11$1.2M−$13.4M
MarginsShare of revenue
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−2222.4%−2051.1%
FY24−1542.6%−1366.5%
FY23−299.9%−253.3%
FY22−320.2%−292.5%
FY21−388.6%−379.9%
FY20−407.5%−551.6%
FY19−943.1%−919%
FY18−1415.4%−1405%
FY17−1025.9%−1046.1%
FY16−726.1%−760.2%
FY15−1142.8%−1233.7%
FY14--
FY13−1820.3%−2151.8%
FY12−507.8%−533.3%
FY11−1136.2%−1147.6%
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$112M
FY24−$123.6M
FY23−$138.4M
FY22−$283.8M
FY21−$213.6M
FY20−$44.2M
FY19−$90.6M
FY18−$41M
FY17−$38.5M
FY16−$30.3M
FY15−$19.9M
FY14−$23.3M
FY13−$15.6M
FY12−$14M
FY11−$12.1M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Fate Therapeutics
  • Healthcare median
−3000%−2000%−1000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFate TherapeuticsHealthcare median
FY25−2051.1%−30.6%
FY24−1366.5%−47%
FY23−253.3%−58%
FY22−292.5%−80.4%
FY21−379.9%−71.8%
FY20−551.6%−62.2%
FY19−919%−46.2%
FY18−1405%−49.6%
FY17−1046.1%−45.9%
FY16−760.2%−36%
FY15−1233.7%−37.8%
FY14-−35.5%
FY13−2151.8%−37.1%
FY12−533.3%−29.1%
FY11−1147.6%−27.9%